Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Rockwell Medical (RMTI) over the last 16 years, with Dec 2024 value amounting to $2.2 million.

  • Rockwell Medical's Depreciation & Amortization (CF) rose 0.18% to $544,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 0.09%. This contributed to the annual value of $2.2 million for FY2024, which is 50.97% up from last year.
  • Latest data reveals that Rockwell Medical reported Depreciation & Amortization (CF) of $2.2 million as of FY2024, which was up 50.97% from $1.4 million recorded in FY2023.
  • In the past 5 years, Rockwell Medical's Depreciation & Amortization (CF) registered a high of $2.2 million during FY2024, and its lowest value of $576,000 during FY2022.
  • In the last 3 years, Rockwell Medical's Depreciation & Amortization (CF) had a median value of $1.4 million in 2023 and averaged $1.4 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first decreased by 19.90% in 2021, then skyrocketed by 150.69% in 2023.
  • Yearly analysis of 5 years shows Rockwell Medical's Depreciation & Amortization (CF) stood at $834,000 in 2020, then fell by 19.90% to $668,000 in 2021, then declined by 13.77% to $576,000 in 2022, then spiked by 150.69% to $1.4 million in 2023, then surged by 50.97% to $2.2 million in 2024.